Nplate and Thrombophlebitis superficial - a phase IV clinical study of FDA data

Summary:

Thrombophlebitis superficial is reported as a side effect among people who take Nplate (romiplostim), especially for people who are male, 60+ old, have been taking the drug for 1 - 6 months also take Carvedilol, and have Idiopathic thrombocytopenic purpura.

The phase IV clinical study analyzes which people have Thrombophlebitis superficial when taking Nplate. It is created by eHealthMe based on reports of 17,818 people who have side effects when taking Nplate from the FDA, and is updated regularly.

What is Nplate?

Nplate has active ingredients of romiplostim. It is often used in idiopathic thrombocytopenic purpura (itp). eHealthMe is studying from 17,850 Nplate users. Check the latest studies of Nplate.

What is Thrombophlebitis superficial?

Thrombophlebitis superficial (swelling (inflammation) of a superficial vein caused by a blood clot) is found to be associated with 519 drugs and 700 conditions by eHealthMe. Check the latest studies of Thrombophlebitis superficial.

On Jul, 29, 2026

17,818 people reported to have side effects when taking Nplate.
Among them, 16 people (0.09%) have Thrombophlebitis superficial.

Could Nplate cause Thrombophlebitis superficial?

Among these 16 people:

How long have people been on Nplate when they have Thrombophlebitis superficial? *

What is the gender of people who have Thrombophlebitis superficial when taking Nplate? *

female: 21.43 %
male: 78.57 %

What is the age of people who have Thrombophlebitis superficial when taking Nplate? *

What are other drugs people take besides Nplate? *

What are other side effects people have besides Thrombophlebitis superficial? *

Death: 4 people, 25.00%
Therapeutic Response Increased (high preventive response): 4 people, 25.00%
Adverse Event: 2 people, 12.50%
Thrombocytopenia (decrease of platelets in blood): 2 people, 12.50%
Pain In Extremity: 2 people, 12.50%
Weight Loss: 1 person, 6.25%
Hypercoagulation (increased tendency for clotting of the blood): 1 person, 6.25%
Haematochezia (passage of stools containing blood): 1 person, 6.25%
Headache (pain in head): 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%

What are the existing conditions these people have? *

Idiopathic Thrombocytopenic Purpura (bleeding disorder in which the immune system destroys platelets, which are necessary for normal blood clotting): 12 people, 75.00%
Upper Respiratory Tract Infection: 1 person, 6.25%
Thrombocytopenia (decrease of platelets in blood): 1 person, 6.25%
Pulmonary Congestion (congestion in the lungs): 1 person, 6.25%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 6.25%
High Blood Pressure: 1 person, 6.25%
Hepatitis (inflammation of the liver): 1 person, 6.25%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 6.25%
Dyspnea (difficult or laboured breathing): 1 person, 6.25%
Cough: 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Nplate and have Thrombophlebitis superficial?

- Check whether Thrombophlebitis superficial is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nplate:

Nplate (17,850 reports)

Browse all side effects of Nplate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Thrombophlebitis superficial:

Thrombophlebitis superficial (519 drugs)

Browse all the conditions that are associated with Thrombophlebitis superficial:

Thrombophlebitis superficial (700 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on romiplostim (the active ingredients of Nplate) and Nplate (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.